These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35918035)

  • 1. Circulating levels of GDF-15 for predicting cardiovascular and cancer morbidity and mortality in type 2 diabetes: Findings from Da Qing IGT and Diabetes Study.
    Qian X; He S; Shen X; Shi N; Gong Q; An Y; Chen Y; Wang J; Li G
    Diabetes Metab; 2022 Nov; 48(6):101380. PubMed ID: 35918035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö Diet and Cancer-Cardiovascular Cohort.
    Bao X; Borné Y; Muhammad IF; Nilsson J; Lind L; Melander O; Niu K; Orho-Melander M; Engström G
    Diabetologia; 2019 Jan; 62(1):78-86. PubMed ID: 30350239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.
    Li G; Zhang P; Wang J; An Y; Gong Q; Gregg EW; Yang W; Zhang B; Shuai Y; Hong J; Engelgau MM; Li H; Roglic G; Hu Y; Bennett PH
    Lancet Diabetes Endocrinol; 2014 Jun; 2(6):474-80. PubMed ID: 24731674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre-diabetic patients:long-term follow-up of Da Qing Diabetes Prevention Study].
    Chen Y; Wang J; An Y; Gong Q; He Y; Zhang B; Li H; Shuai Y; Tang X; Jiang Y; Hong J; Yang W; Hu Y; Li G
    Zhonghua Nei Ke Za Zhi; 2015 Jan; 54(1):13-7. PubMed ID: 25877139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.
    Sen T; Li J; Neuen BL; Arnott C; Neal B; Perkovic V; Mahaffey KW; Shaw W; Canovatchel W; Hansen MK; Heerspink HJL
    J Am Heart Assoc; 2021 Dec; 10(23):e021661. PubMed ID: 34854308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.
    Gong Q; Zhang P; Wang J; Ma J; An Y; Chen Y; Zhang B; Feng X; Li H; Chen X; Cheng YJ; Gregg EW; Hu Y; Bennett PH; Li G;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):452-461. PubMed ID: 31036503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes.
    Pavo N; Wurm R; Neuhold S; Adlbrecht C; Vila G; Strunk G; Clodi M; Resl M; Brath H; Prager R; Luger A; Pacher R; Hülsmann M
    Clin Chem; 2016 Dec; 62(12):1612-1620. PubMed ID: 27756762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer and its predictors in Chinese adults with newly diagnosed diabetes and impaired glucose tolerance (IGT): a 30-year follow-up of the Da Qing IGT and Diabetes Study.
    He S; Wang J; Shen X; Qian X; An Y; Gong Q; Zhang B; Chen B; Zhang L; Chen X; Chen Y; Li G
    Br J Cancer; 2022 Jul; 127(1):102-108. PubMed ID: 35256755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study.
    Chen Y; Zhang P; Wang J; Gong Q; An Y; Qian X; Zhang B; Li H; Gregg EW; Bennett PH; Li G
    Diabetologia; 2021 Jun; 64(6):1279-1287. PubMed ID: 33608769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
    Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
    Diabetes Care; 2010 Jul; 33(7):1567-72. PubMed ID: 20357380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy.
    Bidadkosh A; Lambooy SPH; Heerspink HJ; Pena MJ; Henning RH; Buikema H; Deelman LE
    Diabetes Care; 2017 Jun; 40(6):784-792. PubMed ID: 28341782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes.
    Resl M; Clodi M; Vila G; Luger A; Neuhold S; Wurm R; Adlbrecht C; Strunk G; Fritzer-Szekeres M; Prager R; Pacher R; Hülsmann M
    Heart; 2016 Dec; 102(24):1963-1968. PubMed ID: 27456261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major Adverse Cardiovascular Events and Mortality Prediction by Circulating GDF-15 in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Xie S; Li Q; Luk AOY; Lan HY; Chan PKS; Bayés-Genís A; Chan FKL; Fung E
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.
    Carlsson AC; Nowak C; Lind L; Östgren CJ; Nyström FH; Sundström J; Carrero JJ; Riserus U; Ingelsson E; Fall T; Ärnlöv J
    Ups J Med Sci; 2020 Feb; 125(1):37-43. PubMed ID: 31805809
    [No Abstract]   [Full Text] [Related]  

  • 15. Circulating GDF-15 in relation to the progression and prognosis of chronic kidney disease: A systematic review and dose-response meta-analysis.
    Zhou Z; Liu H; Ju H; Chen H; Jin H; Sun M
    Eur J Intern Med; 2023 Apr; 110():77-85. PubMed ID: 36740468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth differentiation factor-15 is a biomarker for all-cause mortality but less evident for cardiovascular outcomes: A prospective study.
    Bao X; Borné Y; Xu B; Orho-Melander M; Nilsson J; Melander O; Engström G
    Am Heart J; 2021 Apr; 234():81-89. PubMed ID: 33421373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men.
    Wallentin L; Zethelius B; Berglund L; Eggers KM; Lind L; Lindahl B; Wollert KC; Siegbahn A
    PLoS One; 2013; 8(12):e78797. PubMed ID: 24312445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth Differentiation Factor-15 Predicts Death and Stroke Event in Outpatients With Cardiovascular Risk Factors: The J-HOP Study.
    Negishi K; Hoshide S; Shimpo M; Kanegae H; Kario K
    J Am Heart Assoc; 2021 Dec; 10(24):e022601. PubMed ID: 34889104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperinsulinemia and plasma glucose level independently associated with all-cause and cardiovascular mortality in Chinese people without diabetes-A post-hoc analysis of the 30-year follow-up of Da Qing diabetes and IGT study.
    Wang H; He S; Wang J; An Y; Wang X; Li G; Gong Q;
    Diabetes Res Clin Pract; 2023 Jan; 195():110199. PubMed ID: 36481224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.